open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-09-01
Submitted: 2020-02-02
Get Citation

Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010–2019

Jan Styczyński, Krzysztof Czyżewski, Jowita Frączkiewicz, Małgorzata Salamonowicz, Agnieszka Piekarska, Monika Adamska, Przemysław Gałązka, Patrycja Mensah-Glanowska, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Agnieszka Tomaszewska, Kazimierz Hałaburda, Marcin Płonowski, Olga Gryniewicz-Kwiatkowska, Patrycja Zalas-Więcek, Liliana Chełmecka-Wiktorczyk, Ninela Irga-Jaworska, Tomasz Ociepa, Renata Tomaszewska, Lidia Gil
DOI: 10.2478/ahp-2020-0028
·
Acta Haematol Pol 2020;51(3):157-163.

open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-09-01
Submitted: 2020-02-02

Abstract

No epidemiological data exist so far on invasive mucormycosis (IM) in Polish hematopoietic cell transplantation (HCT) and pediatric hemato-oncology (PHO) centers. The objective of this study was to analyze the incidence, clinical course, therapy, and outcome of IM in pediatric and adult patients undergoing HCT and children with hemato-oncological diseases in Poland. A total number of 12425 at-risk patients were retrospectively analyzed, and the period between 2010 and 2019 was included. Patients were analyzed in three groups: nontransplant children with malignancies, children undergoing HCT, and adults after HCT. Twenty-one patients were diagnosed with IM, including 15 children (10 non-HCT, 5 HCT) and 6 HCT adults. Proven IM was confirmed in 18 patients, probable in 2 patients, and possible in 1 patient. Proven IM was diagnosed in 7.1% of all patients with invasive fungal diseases (IFDs), including 8.1% among PHO patients, 5.4% among pediatric HCT patients, and 7.0% among adult HCT patients. Clinically, pneumonia was diagnosed in 10 (47.6%) patients, involvement of the paranasal sinuses was found in 3 (14.3%) patients, gastrointestinal disease was noted in 2 (9.5%) patients, and disseminated mucormycosis was found in 6 (28.6%) patients. The probability of overall survival in IM patients was 0.50 ± 0.11. Infection-related mortality (IRM) was 10% for pediatric nontransplant IM patients and 82% for transplant IM (pediatric + adult) patients ( = 0.004). Among the transplant patients, all adults died within 120 days. IRM for pediatric HCT patients was 60% ( = 0.038). The only prognostic factor was HCT, which adversely influenced survival in IM patients.

Abstract

No epidemiological data exist so far on invasive mucormycosis (IM) in Polish hematopoietic cell transplantation (HCT) and pediatric hemato-oncology (PHO) centers. The objective of this study was to analyze the incidence, clinical course, therapy, and outcome of IM in pediatric and adult patients undergoing HCT and children with hemato-oncological diseases in Poland. A total number of 12425 at-risk patients were retrospectively analyzed, and the period between 2010 and 2019 was included. Patients were analyzed in three groups: nontransplant children with malignancies, children undergoing HCT, and adults after HCT. Twenty-one patients were diagnosed with IM, including 15 children (10 non-HCT, 5 HCT) and 6 HCT adults. Proven IM was confirmed in 18 patients, probable in 2 patients, and possible in 1 patient. Proven IM was diagnosed in 7.1% of all patients with invasive fungal diseases (IFDs), including 8.1% among PHO patients, 5.4% among pediatric HCT patients, and 7.0% among adult HCT patients. Clinically, pneumonia was diagnosed in 10 (47.6%) patients, involvement of the paranasal sinuses was found in 3 (14.3%) patients, gastrointestinal disease was noted in 2 (9.5%) patients, and disseminated mucormycosis was found in 6 (28.6%) patients. The probability of overall survival in IM patients was 0.50 ± 0.11. Infection-related mortality (IRM) was 10% for pediatric nontransplant IM patients and 82% for transplant IM (pediatric + adult) patients ( = 0.004). Among the transplant patients, all adults died within 120 days. IRM for pediatric HCT patients was 60% ( = 0.038). The only prognostic factor was HCT, which adversely influenced survival in IM patients.

Get Citation

Keywords

invasive fungal disease; invasive mucormycosis; children; adults; leukemia; hematopoietic cell transplantation

About this article
Title

Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010–2019

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 3 (2020)

Pages

157-163

Published online

2020-09-01

DOI

10.2478/ahp-2020-0028

Bibliographic record

Acta Haematol Pol 2020;51(3):157-163.

Keywords

invasive fungal disease
invasive mucormycosis
children
adults
leukemia
hematopoietic cell transplantation

Authors

Jan Styczyński
Krzysztof Czyżewski
Jowita Frączkiewicz
Małgorzata Salamonowicz
Agnieszka Piekarska
Monika Adamska
Przemysław Gałązka
Patrycja Mensah-Glanowska
Joanna Drozd-Sokołowska
Anna Waszczuk-Gajda
Agnieszka Tomaszewska
Kazimierz Hałaburda
Marcin Płonowski
Olga Gryniewicz-Kwiatkowska
Patrycja Zalas-Więcek
Liliana Chełmecka-Wiktorczyk
Ninela Irga-Jaworska
Tomasz Ociepa
Renata Tomaszewska
Lidia Gil

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl